Myriad Genetics Inc (MYGN) is a publicly traded Healthcare sector company. As of May 21, 2026, MYGN trades at $3.80 with a market cap of $344.74M and a P/E ratio of -0.86. MYGN moved +6.76% today. Year to date, MYGN is -37.95%; over the trailing twelve months it is -14.38%. Its 52-week range spans $3.53 to $27.55. Analyst consensus is neutral with an average price target of $7.20. Rallies surfaces MYGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for MYGN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $3.80 |
| Market Cap | $344.74M |
| P/E Ratio | -0.86 |
| EPS | $-4.29 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.55 |
| 52-Week Low | $3.53 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $829.00M |
| Net Income | $-399.90M |
| Gross Margin | 69.96% |
7 analysts cover MYGN: 0 strong buy, 2 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $7.20.